CET
Retrospective Evaluation of Biosimilar Cetuximab's Efficacy in Locoregionally Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck: A Multicenter Analysis.
PET scan report/CT scan report
Vital sign
Cetuximab administration
Subsequent Visit
| Cetuximab dosing * | Date of dose * | Dosage * | Any complication * |
|---|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|